Cadila Pharmaceuticals launches Tarzed for breast cancer

Ahmedabad: Ahmedabad-based Cadila Pharmaceuticals Limited has launched Trastuzumab, with the brand name Tarzed. It is a humanized monoclonal antibody, recommended in HER2 positive early breast cancer and metastatic breast cancer.

"It is considered safe and more efficacious compared to conventional treatment medicines for breast cancer. Tarzed is available as 440 mg injection. It is considered safe and more efficacious compared to conventional treatment medicines for breast cancer," a company statement said.

Mentioning the latest audit report of Globocan Incidences which indicated that breast cancer are highest among all types of cancers in Indian population. Through this launch, Cadila wants to strengthens and expand its oncology portfolio.